The "Prescription Drug Price Relief Act," proposed by Sen. Sanders and Rep. Khanna attempts to alleviate high drug prices for Americans as well as monopolies on drug manufacturing. Many, however, have noted that the act shares features with a recent proposal by the trump administration. Others, such as CP3 Director Walid Gellad, expressed skepticism for the Sanders-Khanna. “In my view, it’s generally not a good idea to address high drug prices by labeling almost every brand-name drug as excessively priced and then removing all patent rights from the manufacturer,” Gellad told Vox. “That doesn’t strike the balance we need to address drug prices while maintaining our system of innovation.”